ABSTRACT
Justification Stimulation of early innate anti-viral responses during the early phase of SARS-COV-2 infection oxygen may improve evolution of illness and late pulmonary complications. This may be possible using a TLR agonist such as a probiotic bacterium possessing desirable immunomodulatory properties.
Method We performed a non-contact, open-label, prospective randomized clinical trial comparing intranasally applied Lactococcus lactis W136 with saline irrigation alone in patients within 96 hours of diagnosis of SARS-COV-2 infection not requiring supplemental oxygen.
Results Twenty-three of a planned forty participants aged 18-59 without comorbidities were recruited. Irrigation with intranasal L lactis W136 twice-daily for fourteen days of was associated with a nasal response characterised by increase in the symptom of Facial and Throat pain/discomfort, and with a lesser severity in symptoms of i) Fatigue ii) Olfactory dysfunction and iii) Breathlessness. Safety and tolerability were good, with no acute infections or severe deteriorations.
Interpretation Facial and throat pain may correspond to postulated mechanism of action corresponding to activation of innate defences with antiviral effects and may explain the potentially protective effects seen. Intranasal L lactis W136 irrigations may thus represent a potentially inexpensive, safe, and easily scalable non-antigen based therapeutic for the continuing global SARS-COV-2 pandemic.
Data availability statement Data is available on request from the senior author, Dr Desrosiers: martin-yvon.desrosiers.med@ssss.gouv.qc.ca
Funding This work was supported with internal funds from the Desrosiers laboratory at the Centre de Recherche du Centre Hospitaller de l’Université de Montreal (CRCHUM).
Competing Interests Dr Desrosiers holds equity in Probionase Therapies inc., Which commercialises Lactococcus lactis W136 for chronic rhinosinusitis.
Competing Interest Statement
Dr Desrosiers has an equity stake in Probionase Therapies, Inc., which commercializes Lactococcus lactis W136 for management of symptoms of chronic sinusitis with and without nasal polyposis.
Clinical Trial
ClinicalTrials.gov. identifier: NCT04458519
Funding Statement
This work was supported with internal funds from the Desrosiers laboratory at the Centre de Recherche du Centre Hospitaller Universite de Montreal (CRCHUM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was obtained from the CHUM Institutional Review Board and Ethics committee (Registration No. 20.012) prior to trial performance. Given the innovative character of this trial, a non-objection letter (NOL) was required form Health Canada prior to final approval of the trial by the CHUM IRB. (Health Canada NOL registration number: 249512)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Clinical Trials Registration: www.ClinicalTrials.gov. identifier: NCT04458519
This work has not been presented publicly, and this paper has not been submitted for consideration or publication elsewhere.
Data Availability
Data is available on request from the senior author, Dr Desrosiers, at martin-yvon.desrosiers.med@sss.gouv.qc.ca
